Increased expression of the survival factor Bcl-2 following antibody-mediated blockade of ICOS in the chronic phase of infection has previously been implicated as a mechanism supporting increased survival of effector T cell populations in the inflamed brain [7]. This evidence concerns the gene BCL2 and infection.